The pharmacological therapy for essential tremor (ET) is inadequate, and many patients resort to surgical procedures. Zonisamide is an antiepileptic with several potential mechanisms of action.
(Clin Neuropharmacol 2007;30: 345Y349) E ssential tremor (ET) is one of the most common movement disorders. Primidone, topiramate, and several other medications developed for seizures variably improve ET. Nevertheless, pharmacological therapy for ET is inadequate, and many patients with marked disability resort to surgical procedures. 1 Zonisamide has several potential mechanisms of action. In vitro pharmacological studies suggest that zonisamide blocks sodium channels and reduces voltagedependent, transient inward currents (T-type Ca 2+ currents), consequently stabilizing neuronal membranes and suppressing neuronal hypersynchronization. 2 Although the biochemical pathophysiology of ET is not known, cellular hypersynchronicity is suspected to play a major role. In vitro binding studies have demonstrated that zonisamide binds to the +-aminobutyric acid (GABA)/ benzodiazepine receptor ionophore complex in an allosteric fashion that does not produce changes in chloride flux. 3 Other in vitro studies have demonstrated that zonisamide (concentration, 10Y30 ug/mL) suppresses synaptically driven electric activity without affecting postsynaptic GABA or glutamate responses (cultured mouse spinal cord neurons) or neuronal or glial uptake of [ 3 H]-GABA (rat hippocampal slices). 2 Thus, zonisamide does not seem to potentiate the synaptic activity of GABA. In vivo microdialysis studies demonstrate that zonisamide facilitates both dopaminergic and serotonergic neurotransmission. Zonisamide also has weak carbonic anhydraseYinhibiting activity. Overall, several of these mechanisms are similar to those of topiramate, which has been shown to improve ET. 4 point was the change in the Tremor Study Group rating scale (TSGRS) scores. 5 We also included global impressions and adverse events (AEs). Zonisamide was titrated to a maximum of 200 mg/d in 2 doses for 4 weeks. The subjects could reduce the dose if needed. We included subjects taking either 1 or no other medications for ET. Other ET medications remained at a stable dose throughout the study. The subjects were evaluated at the same time of day and were instructed to avoid alcohol and use similar amounts of caffeine on the assessment day.
METHODS

RESULTS
Twenty-two subjects were enrolled (male, 9; mean age T SD, 65.0 T 12.6 years; mean duration of ET T SD, 25.6 T 17.1 years). Eighteen subjects (81.8%) had a family history of ET. Six dropped because of AEs and lack of effect (n = 4) or just lack of effect (n = 2). These AEs included reduced cognition (n = 3), nausea/diarrhea (n = 1), sedation (n = 1), and dizziness (n = 1). Two were lost to follow-up (Table 1) . Fourteen subjects returned for their complete postmedication evaluation. Ten of these were on another agent for ET, which was kept constant ( Table 2 ). The 14 subjects had also tried and stopped a total of 34 additional medications for ET before study entry. After 3 months (mean T SD, 88 T 34 days), the final dose was 200 mg (n = 11), 150 mg (n = 1), 100 mg (n = 1), and 12.5 mg (n = 1). The TSGRS scores improved from a mean of 28.9 (SD, T9.2) to a mean of 21.1 (SD, T6.5) (P = 0.02, unpaired t test). Seven subjects (50%) had at least a 25% improvement in TSGRS scores. Subjectively, however, only 4 (35%) reported marked or moderate improvement, 3 (25%) reported mild improvement, and 7 (50%) reported no change. Adverse events included decreased concentration/cognition (n = 2), constipation (n = 1), nocturia (n = 1), abdominal pain/diarrhea (n = 1), and sedation (n = 1).
DISCUSSION
Zonisamide significantly (albeit modestly) improved the TSGRS scores in this small group of medically refractory subjects who completed the study. However, a large number of subjects dropped the medication before a final assessment, usually secondary to a combination of poor subjective efficacy and AEs. The main difference in subjects who dropped was that they had previously stopped more medications because of poor efficacy or AE (Table 1 ). Only 1 of the patients who dropped was on concurrent medication at study entry. Overall, 3 subjects reported better subjective response to zonisamide compared with any previous pharmacological intervention. Therefore, zonisamide may be effective in a subgroup of patients, but most subjects did not subjectively benefit.
Several factors may have mitigated or have minimized the drug effect. This was a very refractory group at a tertiary referral center. Most had failed multiple previous medications and were currently taking another medication for ET. It is possible that monotherapy would have resulted in a more robust subjective improvement. We also thought that the patient's subjective response was often less positive than our tremor examination results. This finding is generally consistent with that of a recent controlled trial presented by Zesiewicz et al, 6 which found a 40% improvement in accelerometry scores but relatively little subjective benefit or change on tremor examination. The differences between the studies include duration, the assessment scales, and some inclusion criteria. Finally, the TSGRS has never been validated against global impressions; thus, the clinical meaning of the mean of 7.8-point improvement is not clear.
Another open label study for ET did report similar improvement on the effect of zonisamide compared with that of arotinolol. 7 Finally, we have anecdotally noted inconsistent but sometimes robust improvement on the effect of zonisamide when used for rest tremor in Parkinson disease. Others have also reported improvements in the condition of PD tremor and of other PD motor symptoms. 8, 9 Overall, we think that additional controlled trials are justified for ET.
